Equity Overview
Price & Market Data
Price: $1.01
Daily Change: -$0.04 / 3.96%
Daily Range: $1.00 - $1.05
Market Cap: $239,755,312
Daily Volume: 61,911
Performance Metrics
1 Week: -8.18%
1 Month: 2.96%
3 Months: 3.23%
6 Months: -8.18%
1 Year: -0.82%
YTD: 43.63%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.